Strengthens investor syndicate with participation from new investor BDC Capital's new Thrive Venture Fund
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with